Celcuity Inc.
Could not find a ticker for this position, may be a filing error
A clinical-stage biotech developing gedatolisib, a drug aimed at blocking cancer-driving cell signals to treat advanced breast and prostate cancer. Founded in 2012 by Brian Sullivan and Lance Laing, the company first built CELsignia, a tool that reads living tumor cells, before pivoting to drug development. Its name blends "cell" and "acuity" — a nod to the sharp, precise view the founders wanted of a tumor's inner workings.
Granted 1.0K
Granted 1.5K
Granted 1.5K · Sold 25.0K
Granted 1.5K
Granted 13.5K · Sold 12.0K
Granted 1.5K
Granted 1.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Laing Lance G.Chief Science Officer, Director · 1 transaction | +0.1% | 1.25M | 1.0K | — | — |
| Nigon RichardDirector · 2 transactions | -9.5% | 80.6K | 1.5K | — | — |
| Dalvey DavidDirector · 2 transactions | -26.1% | 66.5K | 1.5K | — | 25.0K |
| Furcht LeoDirector · 1 transaction | +13.9% | 12.5K | 1.5K | — | — |
| Buller Richard EDirector · 13 transactions | +19.6% | 9.3K | 13.5K | — | 12.0K |
| Murphy Polly A.Director · 1 transaction | +30.6% | 6.5K | 1.5K | — | — |
| Romp Charles RDirector · 1 transaction | +711.6% | 1.7K | 1.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -37.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.